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We sent a questionnaire to 38% (1084) of 2817 parents whose daughters had been offered human papillomavirus vaccination and
who had agreed to participate. Of these, 60% (651) returned a questionnaire. Responses suggested that fact sheets and parent
information evenings confirmed, rather than changed, consent decisions. The views of active refusers on safety and efficacy may be
difficult to change, lowering vaccine coverage.
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In the United Kingdom, routine human papillomavirus (HPV)
vaccination for 12–13-year-old girls to prevent cervical cancer has
begun. The highest possible vaccine uptake is required to achieve
maximum impact on future cancer incidence and to ensure
cost effectiveness (Goldhaber-Fiebert et al, 2008). Two parental
acceptability studies in the UK anticipated an uptake of about
80% (Brabin et al, 2006; Marlow et al, 2007a), which would
be similar to the coverage achieved by the cervical screening
programme. As those girls who are not vaccinated may
include some who would not take advantage of future
cervical screening, reducing non-acceptance is important
(Jit et al, 2008).
A school-based programme increases the possibility of high
coverage, but the acceptability of vaccinating adolescents against a
sexually transmitted infection remains uncertain, and the general
public is relatively uninformed, or even misinformed, about
cervical cancer and its prevention (Friedman and Shepheard,
2007; Marlow et al, 2007b). We assessed vaccine acceptability in a
feasibility study ahead of the national vaccine programme. Two
primary care trusts (PCTs) in Greater Manchester that offered
Cervarix (GlaxoSmithKline, Rixensart, Belgium) to girls attending
36 secondary schools achieved a 71% uptake of the first HPV
vaccine dose (Brabin et al, 2008). Here we present the results of a
parental questionnaire survey shortly after the second dose, which
focussed on factors that had influenced the parents’ vaccine
decision and included a small group of respondents who had
declined vaccination.
MATERIALS AND METHODS
The North Manchester NHS Research Ethics Committee approved
the study. Cervarix was offered at 0, 1 and 6 months to 2817 girls
aged 12–13 years between October 2007 and July 2008 (Brabin
et al, 2008). In the covering letter, parents were informed that the
funding source was GlaxoSmithKline and that Cervarix was one of
two licensed vaccines; it explained that the vaccine for the future
national immunisation programme and the policy for vaccinating
older girls had not yet been determined. Parents received
information about cervical cancer and the vaccine, a flier
summarising the content of an educational film for girls (Vallely
et al, 2008), details of parent evenings and a separate consent form
for the follow-up research questionnaire. Information evenings
provided an overview of HPV vaccines and the study aims; the
educational film was shown, followed by a question and answer
session facilitated either by school nurses or by a consultant in
communicable diseases.
Primary care trusts forwarded to the research team the names
and addresses of parents who had agreed to be sent questionnaires.
The questionnaire asked about factors that may have influenced
vaccine consent, including socio-demographic characteristics; the
information sheet; parent information evenings; other information
sources; concerns about vaccine safety and efficacy; and their
child’s wish for vaccination and sexual issues. Responses were
mainly measured using a Likert scale appropriate to the question
asked. Proportions were summarised according to whether
consent was given (‘consenters’) or refused (‘refusers’), and
Fisher’s exact tests were used to assess the significance of
differences between groups. An open question asked parents
who had attended an information session to state whether, and
how, this had influenced their vaccine decision. The responses
were analysed semi-qualitatively.
RESULTS
In all, 38% (1084) of the 2853 eligible parents consented to be
contacted and 60% (651) of these returned a questionnaire,
including 605 consenters and 46 refusers (20% of the non-
vaccinated group). There were no significant differences in the
ages, ethnicity, religion or free school meal entitlement between
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population, fewer questionnaires were returned by parents of
children receiving free school meals (6 vs 13%) or non-white
parents (7 vs 10%), and only 17 were non-Christian.
In total, 97% (628) of the parents had read the information
sheet. Compared with consenters, refusers were less satisfied with
the level of detail provided, were more likely to state that it did not
answer their questions and were largely uninfluenced by its
contents (Po0.001) (Table 1). Parents were least clear about the
length of protection conferred and how the vaccine prevented
cervical cell changes (Table 2). Refusers were more likely than
consenters to remain unclear about the results of clinical trial data
(16 vs 5%; P¼0.01) and HPV types (14 vs 3%; P¼0.004).
The 20% (128) of parents who attended an information evening
comprised 32% (14) refusers and 19% (114) consenters
(P¼0.049). Of the 90% (115) who expressed their view on the
evening, 26% (30) stated that it had no influence on their vaccine
decision. Some parents valued the opportunity to talk to a health
professional for ‘independent’ advice and to hear more detailed
information, explained in a way they understood. They liked to
hear the views of other parents, which introduced them to new
issues, and found the discussions useful and enjoyable. Predomi-
nantly, parents used words such as ‘reassured’, ‘confirmation’ and
‘confidence’, although for refusers this generally signified con-
firmation that other parents shared their reservations.
In all, 33% (215) of the parents gained information on the vaccine
from television, 24% (152) from newspapers, 18% (113) from the
internet and 6% (100) from a healthcare provider. Friends and
relations (14%), radio (13%) and magazines (6%) were less often
cited. Only 14% (88) based their decision solely on the information
provided by the vaccine programme. Refusers actively sought
additional information more often than consenters, citing the
internet or health professionals as sources (48 vs 27%, P¼0.006).
More refusers than consenters had concerns about vaccine
safety in general, side effects and booster doses (Table 3).
Compatibility of the two available vaccines worried 57% (26) of
refusers but only 16% (94) of consenters (Po0.001). Asked
whether the HPV vaccine would encourage their child to become
more sexually active, 77% (494) responded ‘not at all’, 19% (124)
‘not much’, 3% (21) ‘quite’ and 1% (3) were ‘very’ concerned.
Refusers were more likely to be ‘very’ or ‘quite’ concerned (11% (5)
vs 3% (19); P¼0.021).
In addition, 97% (628) of parents reported discussing the
vaccine with their daughters. Asked whether their daughters
wished to be vaccinated, consenters and refusers, respectively,
responded ‘Yes’ [83% (487) vs 19% (8)]; ‘No’ [4% (25) vs 50%
(21)]; ‘It was not her decision’ [11% (63) vs 29% (12)]; or ‘Don’t
Know’ [2% (11) vs 2% (1)] (Po0.001)]. They did not differ with
regard to whether boys should be vaccinated. Altogether 52% (328)
said ‘Yes’, 5% (33) said ‘No’, 32% (203) would ‘Leave it to the
experts to decide’ and 11% (72) ‘Didn’t Know’.
DISCUSSION
Although parents who responded were not familiar with HPV
vaccination, the information they received through PCTs only
partly influenced their vaccine decision. They mainly sought
reassurance about vaccine safety, but as the vaccine is new and
phase 4 trials are ongoing doubts about its long-term safety cannot
Table 1 Respondent’s view of the information sheet
Consenters Refusers
Missing n % n % P-value
a
Did you find the information sheet easy to read?
Yes 404 69 29 67 0.784
Mostly 26 158 27 12 28
Partly 20 4 2 5
Did it give the level of detail you wanted?
Too little 65 11 20 47 o0.001
The right amount 29 511 88 23 53
Too much 3 1 0 0
Did you find the information sheet answered your questions?
Yes 239 41 5 12 o0.001
Mostly 29 285 49 15 35
Partly 52 9 17 39
No 3 1 6 14
Did the information sheet influence your decision?
A lot 79 14 2 5 o0.001
Quite a lot 34 238 41 9 21
A little 190 33 17 41
Not at all 68 12 14 33
aFisher’s exact test.
Table 2 Parental assessment of the clarity of the facts in the information
sheet
Consenters Refusers
Facts Missing n % n % P-value
HPV is the main cause of cervical cancer
Very clearly 285 49 22 50 1
Clearly 30 283 49 22 50
Not clearly 9 2 0 0
Adolescents are at risk of HPV when they start having sex
Very clearly 284 49 27 62 0.24
Clearly 31 279 49 16 36
Not clearly 13 2 1 2
Vaccine prevents HPV 16 and 18
Very clearly 258 45 20 46 0.004
Clearly 32 301 52 18 41
Not clearly 16 3 6 14
Clinical trials show vaccine prevents persistent infection
Very clearly 214 37 16 37 0.010
Clearly 34 334 58 20 47
Not clearly 26 5 7 16
The vaccine prevents changes to cervical cells
Very clearly 155 27 8 19 0.069
Clearly 34 354 62 25 58
Not clearly 65 11 10 23
The vaccine provides protection for at least 5 years
Very clearly 165 29 13 30 0.32
Clearly 34 310 54 19 44
Not clearly 99 17 11 26
Condoms do not offer 100% protection against HPV
Very clearly 218 38 15 37 0.97
Clearly 35 304 53 23 56
Not clearly 53 9 3 7
Women will still need to go for cervical smears
Very clearly 265 46 17 43 0.81
Clearly 37 269 47 21 52
Not clearly 40 7 2 5
The vaccine does not protect if you already have HPV 16/18
Very clearly 212 37 14 35 0.58
Clearly 42 301 53 24 60
Not clearly 56 10 2 5
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adolescent HPV vaccine coverage may, like the measles, mumps
and rubella (MMR) vaccine (Smith et al, 2007), not reach the
desired level, or that achieved for most infant vaccines. Of concern
is the fact that 50% of refusers stated their daughters did not wish
to be vaccinated because we do not know whether these girls will
take advantage of cervical screening in future.
This is the first study to address parental acceptance of
adolescent HPV vaccination within a vaccine programme.
Inevitably, it is likely that those responding over-represent the
more engaged, articulate parents with stronger views. A return rate
of 60%, representing a quarter of the general population, is
comparable to telephone surveys on HPV acceptability (Con-
stantine and Jerman, 2007; Ogilvie et al, 2007) and higher than a
Dutch postal survey (Lenselink et al, 2008). Parents who do not
return questionnaires may also be less responsive to a vaccine
invitation. A recent study of 14-year-old Belgian adolescents
reported lower general vaccine coverage rates for children of
single, divorced parents and larger families (X4 children)
(Vandermeulen et al, 2008). The sample did include active refusers
(7% of the sample compared with 8% of the population) who tend
to be better educated and may hold strong beliefs, but we do not
have any information about those who did not respond to the
vaccine invitation, and more work is required to understand this
group.
Dempsey et al (2006) reported no effect of written information
on HPV vaccine acceptability. We further report that information
evenings were attended by a minority of parents, with refusers
most likely to attend, whose views were not substantially altered as
a result. The literature on childhood vaccination shows that
parents who believe in vaccination tend to comply with, rather
than make, an informed decision. (Tickner et al, 2007). Worries
about MMR have increased public scepticism; therefore, health
professionals giving information to parents need to be well
prepared with robust, up-to-date information on vaccine safety
and other issues. Some refusers cited concerns about vaccine
compatibility. This arose from a perception that a quadrivalent
must be inherently ‘better’ than a bivalent vaccine, especially as
other countries had already selected it. Misinterpretation of the
licensing process led to parents waiting to see if the quadrivalent
vaccine would be selected for the national programme, even
though their daughters might not be eligible (i.e. if there were no
catch-up programme). Tailored written information on safety
issues could also be prepared, but parents may have taken a
decision based on beliefs and attitudes that are difficult to modify.
CONCLUSIONS
Despite some unease about the safety of HPV vaccination, most
parents who responded wished to protect their daughters from
cervical cancer and comply with vaccine recommendations.
Although there is no evidence of bias, the responders represent a
quarter of the population in two PCTs; hence, caution is needed in
extrapolating the results to the general population. It remains
uncertain whether HPV vaccination coverage will exceed cervical
screening coverage. Parents may listen to health professionals, who
should aim to raise the uptake by communicating the latest
scientific data to refusers and dispelling misperceptions about the
vaccine.
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